India DGFT Notification No. 41/2025-26 — Minimum Import Price on Sulfadiazine API

Mechanism

The notification inserts a new policy condition against ITC-HS codes 29359013 and 29359090 (sulphonamide compounds, including Sulfadiazine API), both of which previously carried a "Free" import policy with no specific condition. Any consignment with a declared CIF invoice value below Rs. 1,774/kg is reclassified to "Restricted," meaning the importer must obtain a DGFT Regional Authority licence before Customs clearance — a price-floor gate rather than a tariff or outright ban. The restriction runs from 10 October 2025 to 30 September 2026.

Strategic context

Sulfadiazine is a sulphonamide-class antibiotic API used in both human formulations (e.g. silver sulfadiazine burn-treatment creams, co-trimoxazole combinations) and veterinary/agricultural use. This is the same DGFT instrument — a Chapter 29 CIF price floor rather than a formal DGTR anti-dumping investigation — later used for potassium clavulanate (2025-12-18-india-dgft-mip-potassium-clavulanate, December 2025) and for penicillin G/6-APA/amoxycillin (2026-01-29-india-dgft-mip-penicillin-6-apa-amoxycillin, January 2026), making this the first documented instance in a recurring Chapter 29 bulk-drug review cycle. It sits alongside India's PLI Bulk Drugs scheme (2020-07-21-india-pli-bulk-drugs-ksm-di-api) as the import-protection half of a build-then-shield strategy for domestic antibiotic-API capacity.

Why severity 2

• Narrow scope: a single API product line, not a sectoral tariff or blanket

import ban.

• Time-limited: an ~11.5-month window (10 Oct 2025 – 30 Sep 2026), consistent

with India's pattern of using MIP as a reversible pressure tool.

• EOU/SEZ/Advance Authorisation exemptions preserve export-oriented

formulation manufacturers' access to competitively priced imports.

• Quantified via a disclosed CIF threshold (Rs. 1,774/kg = severity_basis:

quant), anchoring the measure to a specific price floor rather than a blanket restriction.

Downstream implications

• Indian bulk-drug/API manufacturers. Domestic Sulfadiazine producers

gain a price floor against sub-threshold imports, similar to the protection later extended to potassium-clavulanate and penicillin-family producers.

• Chinese, French and Israeli exporters (per GTA state-act 94758).

Lose access to the sub-threshold segment of the Indian market; above-floor exports remain permitted.

• Formulation exporters using Sulfadiazine as an input (e.g. silver

sulfadiazine burn-cream manufacturers). Insulated via EOU/SEZ/AA exemptions, preserving cost-competitive sourcing for re-export production.

Open questions

• Whether DGFT renews the restriction past 30 September 2026 or escalates to

a formal DGTR anti-dumping investigation.

• The scale of Indian domestic Sulfadiazine API production capacity and

which specific manufacturers benefit (not disclosed in available sources).

• Whether the Rs. 1,774/kg threshold is revised if global pricing shifts,

which would test whether the floor is calibrated to protect margin or merely block loss-leading dumping.